Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
- Corax Consultants LLC
- 29. März 2024
- 1 Min. Lesezeit
BOSTON, March 29, 2024 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX,“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ending December 31, 2023, and provided recent business highlights. Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
Kommentare